A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression
- Registration Number
- NCT04383691
- Lead Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd.
- Brief Summary
The study evaluates the efficacy and safety of lurasidone compared with placebo in treating Bipolar I Depression.
- Detailed Description
The primary objective is to compare the efficacy of lurasidone (20-120 mg/day) monotherapy with that of placebo in patients with Bipolar I Depression by assessing the change from baseline in the MADRS total score at Week 6.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 124
- Patients who have provided written voluntary consent in person after receiving and understanding adequate explanation about the study, including the objectives, content, expected therapeutic and pharmacological effects, and risks.
- Outpatients who are aged 18 through 65 years at time of informed consent.
- Patients with bipolar I disorder, most recent episode depressed, without rapid cycling disease course ( no less than 4 episodes of mood disturbance in the 12 months prior to screening), and without psychotic features (diagnosed by DSM-5 criteria).
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Lurasidone Lurasidone HCl Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8. Placebo Placebo Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
- Primary Outcome Measures
Name Time Method Change from baseline in the MADRS total score at Week 6 Baseline/ week 6 Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.
- Secondary Outcome Measures
Name Time Method Change from baseline in the CGI-BP-S (depression) score at Week 6 Baseline/ week 6 Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression. The CGI depression score ranges from a minimum of 1 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (26)
Beijing Anding Hospital capital medical university
🇨🇳Beijing, Beijing, China
Beijing HuiLongGuan Hospital
🇨🇳Beijing, Beijing, China
Peking University 6th Hospital
🇨🇳Beijing, Beijing, China
Chongqing Mental Health Center
🇨🇳Chongqing, Chongqing, China
Xiamen Xianyue Hospital
🇨🇳Xiamen, Fujian, China
Guangzhou Huiai Hospital
🇨🇳Guangzhou, Guangdong, China
Shenzhen Kangning Hospital
🇨🇳Shenzhen, Guang, China
Hebei Provincal Mental Health Center
🇨🇳Baoding, Hebei, China
The 2nd Affiliated Hospital of Xinxiang Medical University
🇨🇳Xinxiang, Henan, China
Zhumadian Psychiatric Hospital
🇨🇳Zhumadian, Henan, China
Scroll for more (16 remaining)Beijing Anding Hospital capital medical university🇨🇳Beijing, Beijing, China